论文部分内容阅读
与结直肠息肉相似,几乎所有家族性腺瘤性息肉病(FAP)病人发生十二指肠息肉,这也是癌症的前驱病变。对十二指肠息肉病的手术或内镜治疗都存在复发的危险。用苏林酸(sulindac)治疗的作用有限。COX-2抑制剂不抑制COX-1,在鼠FAP模型中见其使息肉退缩。此研究旨在检查COX-2抑制剂celecoxib对FAP病人的十二指肠息肉病所起作用。 病人和方法:此研究为随机双盲、安慰剂对照研究以调查celecoxib对缩小十二指肠病变面积百分率和改善十二指肠息肉病程度范围的作用和安全性。83例FAP中男性47例,平均年龄34岁。其中77例结直肠中至少有5枚腺瘤。
Similar to colorectal polyps, duodenal polyps occur in almost all familial adenomatous polyposis (FAP) patients, which is also a precursor to cancer. Surgery or endoscopic treatment of duodenal polyposis are at risk of recurrence. The effect of treatment with sulindac is limited. COX-2 inhibitors do not inhibit COX-1, which is seen in murine FAP models to constrict polyps. The aim of this study was to examine the role of the COX-2 inhibitor celecoxib in the treatment of duodenal polyposis in FAP patients. Patients and Methods: This is a randomized, double-blind, placebo-controlled study to investigate the role and safety of celecoxib in reducing the area percentage of duodenal lesions and improving the extent of duodenal polyposis. There were 47 males in 83 cases of FAP, with an average age of 34 years. 77 of them had at least 5 adenomas in the colorectum.